Areas: ,

In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine

After tumour cell vaccination, tumour cells were found to be exclusively inside the spleen if the injection had been set directly into the spleen. The location of immunisation is a factor influencing the efficiency of tumour cell vaccination.
The research team from the Charité in Berlin showed before how gene-modified vaccines delivered directly inside the spleen provoked antigen cross-presentation by splenic antigen-presenting cells (not ).

In their recent study Sophie Cayeux and her team analysed the way in which splenic cells and antigen-specific interact. The scientists used tumour cells expressing . In this condition are needed to induce a cytotoxic response of . By using bioluminescence imaging of expressing EL4- cells the team could proof that after splenic injection tumour cells are exclusively situated in the spleen.

Adoptively in vivo transferred 5,6- carboxy-succinimidyl-fluorescein-ester-labelled transgenic CD4+KJI-26+ cells that were specific for the class II OVA323-339 peptide proliferated in the spleen. The cells were only transiently activated and produced and and not .

Splenic cells are able to reduce responses specific for the spleen. In doing so the antitumour systemic immunity is weakened.

Related antibodies on

Antibodies for the research area immunology:

Antibodies for the research area oncology: